Monopar Therapeutics Inc. Other Current Assets
Monopar Therapeutics Inc. (MNPR) had Other Current Assets of $464.73 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:OtherAssetsCurrent · last filed 2026-08-12
- 2026-06-30: Other Assets, Current $464.73K.
- 2026-03-31: Other Assets, Current $250.90K.
- 2025-12-31: Other Assets, Current $63.74K.
- 2025-09-30: Other Assets, Current $414.82K.
| Period end | Other Assets, Current |
|---|---|
| 2026-06-30 | $464.73K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $250.90K 10-Q · filed 2026-05-14 |
| 2025-12-31 | $63.74K 10-Q · filed 2026-08-12 |
| 2025-09-30 | $414.82K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $497.29K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $523.56K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $78.87K 10-K · filed 2026-03-27 |
| 2024-09-30 | $49.57K 10-Q · filed 2024-11-08 |
| 2024-06-30 | $61.02K 10-Q · filed 2024-08-09 |
| 2024-03-31 | $118.99K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $66.43K 10-K · filed 2025-03-31 |
| 2023-09-30 | $73.19K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $109.87K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $106.82K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $45.98K 10-K · filed 2024-03-28 |
| 2022-09-30 | $55.70K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $189.18K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $193.63K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $217.75K 10-K · filed 2023-03-23 |
| 2021-09-30 | $106.80K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $95.56K 10-Q · filed 2021-08-12 |
| 2020-12-31 | $62.69K 10-K · filed 2022-03-24 |
| 2019-12-31 | $15.71K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |